BACKGROUND: More accurate biomarkers in cervical cytology screening could reduce the number of women unnecessarily referred for biopsy. This study investigated the ability of p16/Ki-67 dual staining to predict high-grade cervical intraepithelial neoplasia (CIN) in human papillomavirus (HPV)-positive women from the Norwegian Cervical Cancer Screening Program. METHODS: Automated p16/Ki-67 dual staining was performed on liquid-based cytology samples from 266 women who were HPV-positive at their secondary screening. At a mean of 184 days after p16/Ki-67 staining, 201 women had a valid staining result and a conclusive follow-up diagnosis (histological diagnosis or HPV-negative diagnosis with normal cytology findings). The sensitivity and specificity for predicting the follow-up diagnosis were compared for cytology, p16/Ki-67 dual staining, and their combination. RESULTS: Sixty-seven percent of the study sample was p16/Ki-67-positive. The sensitivity of p16/Ki-67 staining for predicting CIN-2/3 was statistically significantly higher than the sensitivity of cytology (0.88 vs 0.79; P 5.008), but this was not true for the prediction of CIN-3 (0.94 vs 0.88; P 5.23). The specificity of cytology for predicting CIN-3 was significantly higher than the specificity of p16/Ki-67 staining (0.35 vs 0.28; P 5.002), but this was not true for CIN-2/3 (0.35 vs 0.31; P 5.063). For predicting CIN-2/3 and CIN-3, combination testing gave potentially better sensitivity (0.95 and 0.96, respectively) and better specificity (0.49 and 0.50, respectively).
INTRODUCTION
Well-established cervical cancer screening programs have resulted in a low cervical cancer incidence in many countries, and substantial differences in incidence can be seen between countries with and without such programs. 1 High-risk human papillomavirus (HPV) types have been identified as the cause of more than 99% of cervical cancers and precancerous lesions. 2 HPV-16 is the most common and most carcinogenic HPV type; moderate-to high-grade (grade 2/3) cervical intraepithelial neoplasia (CIN), caused by HPV-18, is also fairly common and is poorly detected by cytology and colposcopy. 3 All this makes HPV testing increasingly relevant as a screening method for identifying women at risk of developing CIN-2/3. The Norwegian Cervical Cancer Screening Program (NCCSP) is a cytology-based program that has been in place since 1995. In 2005, secondary screening with HPV testing was implemented to triage women with minor cytological abnormalities such as atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSILs). An observational study comparing two 3-year screening periods before and after the implementation of HPV secondary screening found that HPV testing decreased the cumulative incidence of CIN-2/3 from 2.7% to 1.0%, increased the positive predictive value from 42% to 48%, and thus led to better risk stratification. 4 A number of studies have shown that primary screening with HPV testing is more sensitive than cytology for predicting CIN-2/3, but the specificity is lower. 5, 6 Another benefit of primary screening with HPV testing is that highrisk, HPV-negative women (approximately 90%) can immediately return to routine screening without cytology, and their recommended screening interval can safely be extended because the long-term risk of CIN-2/3 is very low for these individuals. However, primary screening with HPV may also result in an increased number of referrals for colposcopy for women with harmless, transient infections that do not require treatment; this thus places an extra burden on women, increases health care costs, and creates an increased workload for gynecologists and pathologists. 7 More specific diagnostic biomarkers for HPVpositive women are needed to reduce the number of unnecessary colposcopies and biopsies, and the prolongation of screening intervals, as recommended for HPV primary screening, will also increase the need for more sensitive tests. 7 Different biomarkers have been proposed to identify persistent infections with high-risk HPV types, including p16/Ki-67 dual staining of cytology samples. p16 (also known as p16INK4a) is a cyclin-dependent kinase inhibitor that is overexpressed when the cell-cycle regulatory retinoblastoma protein is inactivated by highrisk HPV E7 oncoproteins; p16 expression is thus a surrogate marker for this event. 8 Ki-67 is a marker of cell proliferation, which is a key feature of CIN progression and is highly correlated with the grade of dysplastic change in the epithelium. 9 p16 and Ki-67 have long been used in histology to detect and confirm the presence of CIN-2/3.
10-12
The diagnostic accuracy of p16/Ki-67 dual staining of cytology samples has recently been tested, 13, 14 and the studies concluded that this method had similar sensitivity and significantly higher specificity in comparison with HPV testing among women with normal cytology, ASCUS, or LSILs. In the current study, using the CINtec PLUS kit, we aimed to determine the clinical performance of a fully automated p16/Ki-67 dual-staining protocol for triaging HPVpositive women with normal cytology, ASCUS, or LSILs who were attending the NCCSP by investigating the ability of dual staining to predict CIN-2/3 in these women.
MATERIALS AND METHODS

NCCSP
Within the framework of the NCCSP, women undergo primary screening by liquid-based cytology (LBC). Women with normal cytology are returned to routine screening; women with high-grade squamous intraepithelial lesions (HSILs) or atypical squamous cells, cannot exclude high-grade lesions (ASC-H) are referred for colposcopy; and women with ASCUS or LSILs are sent to secondary screening. Two algorithms for secondary screening have been used in recent years, and both include HPV testing.
The first secondary screening algorithm was in place until June 2014. During this time, NCCSP guidelines stated that a second round of screening was to be performed after 6 to 12 months in women with a primary screening result of ASCUS or LSIL; this consisted of repeat cytology and HPV testing. Women who were HPVpositive and had ASCUS or worse cytology in this second round of screening were referred for colposcopy and biopsy, whereas HPV-positive women with normal cytology were sent to a third round of screening 6 to 12 months later, again with cytology and HPV testing. Women with a persistent HPV infection in the third round of screening were referred for colposcopy and biopsy, regardless of the cytology results. HPV-negative women with normal or ASCUS cytology during any of the aforementioned rounds were referred back to routine screening.
The guidelines changed in June 2014, at which time the second algorithm was implemented. In this algorithm, secondary HPV screening consists of HPV reflex testing of women with ASCUS and LSILs; that is, LBC samples of women with a primary screening result of ASCUS or LSIL are tested for HPV immediately rather than 12 months later.
Study Sample
Within the framework of the NCCSP, LBC samples from 25,111 women were sent to Stavanger University Hospital (Stavanger, Norway) for cytology screening between December 2013 and August 2014. Of these women, 1147 were sent to secondary screening with HPV testing and, when applicable, repeat cytology according to the guidelines of the NCCSP.
Of the 1147 women sent to secondary screening, 703 were HPV-negative, and 444 were HPV-positive. Among the HPV-positive women, 273 had sufficient material left for p16/Ki-67 dual staining in their LBC samples from the secondary screening. 15 After the exclusion of 6 patients who did not give consent for their samples to be used and 1 woman with vaginal intraepithelial neoplasia, 266 women were included in the current analysis (Fig. 1 ). 
p16/Ki-67 Dual Staining and Immunocytochemistry
LBC samples from the 266 women in the study sample were used for p16/Ki-67 dual staining, which was performed at Haukeland University Hospital (Bergen, Norway). The time interval between secondary screening (ie, sample collection) and p16/Ki-67 dual staining varied and was categorized as less than 6 weeks, 6 to 8 weeks, or more than 8 weeks. The samples were suspended in ThinPrep media (Hologic, Inc) and were used to make slides on a ThinPrep 2000 processor (Hologic, Inc). After thorough mixing, a circular imprint with a diameter of 20 mm of single-layer cells was made on ThinPrep microscope slides for special processing (Hologic, Inc) according to the manufacturer's instructions. The slides were transferred into a 95% reagent-grade ethanol solution for a minimum of 10 minutes and left to dry horizontally on a flat surface, after which p16/Ki-67 dual staining was performed within 3 days. Immunocytochemistry was performed in 3 batches with the CINtec PLUS cytology kit on a fully automated slide-stainer platform (Ventana Benchmark Ultra; Roche Diagnostics). The kit consists of a cocktail of a monoclonal mouse antibody (clone E6H4) directed toward human p16INK4a protein and a primary recombinant rabbit antibody (clone 274-11 AC3) directed toward human Ki-67. After cell conditioning, inhibition of p16/Ki-67 Staining of HPV-Positive Women/Ovestad et al
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April 2017 endogenous peroxidase activity, and incubation with the primary antibody cocktail, 2 detection systems optimized for cervical cytology specimens were used: 1) a goat antimouse secondary antibody covalently attached to a horseradish peroxidase-conjugated tertiary antibody for the detection of the monoclonal mouse antibody (clone E6H4) and 2) a goat anti-rabbit secondary antibody covalently attached to an alkaline phosphatase-conjugated tertiary antibody for the detection of the rabbit recombinant antibody (clone 274-11 AC3). A chromogenic reaction based on the horseradish peroxidase-mediated conversion of 3,3-diaminobenzidine tetrahydrochloride results in a brown precipitate at the p16INK4a antigen site, and an alkaline phosphatase-mediated conversion of Fast Red with naphthol phosphate results in a red precipitate at the Ki-67 antigen site. Finally, the slides were automatically counterstained with hematoxylin and a bluing reagent. The slides were first mounted with an aqueous mounting medium (CC/Mount aqueous mounting medium; Sigma-Aldrich, St. Louis, Mo) before they were coverslipped with a permanent mounting medium.
Evaluation of p16/Ki-67 Dual Staining
The definition of a p16/Ki-67 dual-stained cell is a cervical epithelial cell with simultaneous brown cytoplasmic immunostaining and red nucleus immunostaining. Dual staining can be seen in a single cell, a group of cells, or clusters of cells, and it is important to ensure that the cytoplasm is in the same plane of focus as the nucleus. In accordance with the manufacturer's instructions, samples were considered p16/Ki-67-positive if at least 1 cervical epithelial cell was stained with both a red nuclear stain for Ki-67 and a brown cytoplasmic stain for p16INK4a. If this criterion was not met; the staining result was considered negative (Fig. 2 ). Samples were scored as inconclusive if they did not contain an adequate number of cells (>4 cells per field of vision and a minimum of 10 fields of vision with a 403objective) or if they did not contain at least 1 red signal (Ki-67) and 1 brown signal (p16). Superficial cells that were negative for p16INK4a expression served as an internal negative control to assess background staining. The whole area with cells was screened systematically with a 10 3 objective, and positive cells were confirmed with the 40 3 objective. Each sample was scored by 2 independent observers: one from a group consisting of 3 trained cytology technicians (J.L.D.L., B.M.D., and P.M.) and another from a team of 2 trained students (M.B.D. and E.H.) All observers were blinded to the cytology results. In case of discrepancies, a consensus among all 5 observers was obtained during a multiheaded microscope session.
Follow-Up Diagnoses
Conclusive follow-up diagnoses (histological diagnosis or HPV-negative diagnosis with normal cytology findings) were retrieved in October 2015 from the pathology patient registry system at the Pathology Department of Stavanger University Hospital. Immunohistochemistry with a marker for Ki-67 was used on sections from all biopsies to support the grading of CIN. Diagnoses were set an average of 184 days (range, 11-648 days) after p16/Ki-67 dual staining. Among the 266 women studied, 20 (8%) had an HPV-negative result during the third round of secondary screening and were referred back to routine screening. Forty-two women (16%) were missing cytology results, biopsy results, or both at follow-up, and 7 of these women were still waiting for a new screening round. The remaining 204 (77%) underwent biopsy: 69 (34%) were normal or had metaplasia, 42 (21%) were diagnosed with CIN-1, 37 (18%) were diagnosed with CIN-2, and 56 (27%) were diagnosed with CIN-3.
Statistical Analysis
SPSS Statistics 22 (SPSS, Inc, Chicago, Ill) was used to estimate the j agreement between the 2 observer groups 
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RESULTS
The median age of the study sample was 33 years (range, 25-69 years; interquartile range, 28-43 years). The prevalence of the analyzed samples for CIN-2 and CIN-3 was 17% (34 of 201) and 25% (50 of 201), respectively. The composition of the samples combining results of cytology and biopsies are listed in Table 2 .
p16/Ki-67 Dual Staining
The j agreement between the 2 observers for their initial p16/Ki-67 dual-staining classifications was high (j 5 .8).
In total, 63 of 266 women (24%) in our study sample were p16/Ki-67-negative, and 178 of 266 (67%) were p16/Ki-67-positive, whereas 25 of 266 (9%) had inconclusive p16/Ki-67 results ( Table 1) . Ninety of the LBC samples (34%) were 6 weeks old or less at the time of p16/ Ki-67 dual staining, 46 (17%) were 6 to 8 weeks old, and 130 (49%) were more than 8 weeks old (8-16 weeks). There was no significant association between the age of LBC samples and the results of p16/Ki-67 dual staining (P 5 .47).
p16/Ki-67 Dual-Staining and Cytology Results According to Follow-Up Diagnoses
In our study group, 241 women (91%) had a valid p16/ Ki-67 dual-staining result, and 201 of these women (83%) also had a conclusive follow-up diagnosis (Fig. 1) . The overall agreement between p16/Ki-67 staining and cytology was low for samples with a conclusive follow-up diagnosis (j 5 .23). Agreement ranged from fair for CIN-3 (j 5 .40) and normal biopsies (j 5 .25) to poor for CIN-2 (j 5 -0.7) and CIN-1 (j 5 .15; Table 3 ).
Sensitivity and Specificity
Sensitivities, specificities, positive predictive values, and negative predictive values were calculated for CIN-2/3 and for CIN-3 alone. The sensitivity of p16/Ki-67 was significantly higher (P 5 .008) than the sensitivity of cytology for predicting CIN-2/3 in our women with conclusive followup diagnoses. However, for CIN-3 alone, there was no significant difference between the 2 methods (P 5 .23). The specificity of cytology for predicting CIN-3 in this same group was significantly higher than the specificity of p16/ Ki-67 dual staining (P 5 .002), but this was not the case for CIN-2/3 (P 5 .063).
When calculating sensitivities and specificities for combination testing, we used 2 different definitions: a specific definition, in which only samples that were positive for both cytology and p16/Ki-67 dual staining were counted as positive (ie, if cytology, p16/Ki-67 staining, or both were negative, it was counted as negative), and a sensitive definition, in which samples that were positive for cytology, p16/Ki-67 staining, or both were counted as positive (ie, if both tests were negative, the sample was counted as negative).
Using the specific definition for the prediction of CIN-2/3 and CIN-3 alone increased the specificity to 0.49 and 0.50, respectively, whereas using the sensitive definition increased the sensitivity to 0.95 and 0.96, respectively (Table 4) .
DISCUSSION
We calculated the sensitivity and specificity of p16/Ki-67 dual staining, cytology, and a combination of these methods for predicting CIN-2/3 or CIN-3 among women attending the NCCSP who were HPV-positive at the secondary screening. The sensitivity of p16/Ki-67 dual staining for predicting CIN-2/3 was significantly higher than the sensitivity of cytology, but this was not the case for the prediction of CIN-3. When a specific definition was used, combination testing showed increased specificity while still showing acceptable sensitivity in comparison with using both methods individually. The automated immunostaining platform Ventana Benchmark Ultra has already been validated for immunohistochemical analysis, 16 but to our knowledge, we are the first to describe immunocytochemical p16/Ki-67 dual staining with the CINtec PLUS kit on this platform.
Comparable Studies
Two studies used the Dako autostainer with the CINtec PLUS kit for processing slides. 17, 18 For women aged 30 years or older, the sensitivity of this method for detecting CIN-2/3 was comparable to ours. However, the specificities reported in these studies, which also included HPVnegative samples, were considerably higher than our results. p16/Ki-67 dual staining presumes the presence of an HPV infection and is indicative of cell transformation caused by the HPV E7 oncoprotein. The inclusion of HPV-negative women would increase the number of healthy women with a low probability of a positive p16/Ki-67 result. Therefore, the specificity in settings including HPV-negative women must be expected to be higher than what was seen in our study. Our results are comparable to those of an earlier HPV-based screening study 19 that found similar sensitivity and specificity for detecting CIN-2 1 with a combination of p16/Ki-67 dual staining and cytology (ASCUS or worse) in women who were HPV-positive at the primary screening. However, the specificity for dual staining alone was somewhat higher than ours. Our study had a higher proportion of samples positive for dual staining (67% vs 35%). Because of the rather long time interval between primary LSIL or ASCUS cytology and secondary HPV screening in our study, it is likely that we had a larger proportion with a persistent HPV infection, and this naturally challenges the ability of p16/Ki-67 dual staining to correctly identify those without disease.
Other studies conducted on p16/Ki-67 dual staining [20] [21] [22] [23] [24] reported comparable sensitivities but, again, higher specificities as observed in the current study. The aforementioned studies differed in terms of the proportion of different cytological results within the study sample and the HPV status of the women included. In addition, differences in diagnostic thresholds or criteria for CIN-2/3, such as the use of adjunctive markers, may have contributed to the performance variation observed across studies. When we consider p16/Ki-67 dual staining for clinical use, the most relevant results are from studies conducted in settings that are similar to the practice in which the test is to be implemented. 25 
Strength and Limitations of the Study
It is noteworthy that for logistic reasons, at the time of p16/Ki-67 staining, the age of the LBC samples exceeded the manufacturer's recommendations. We controlled for this in our analysis by examining the correlation between the age of the LBC sample and the outcome of p16/Ki-67 staining. No significant difference was detected in p16/Ki-67 dual staining due to the age of the sample. One might question whether a single dual-stained cell is sufficient for positivity of the sample, as recommended by the manufacturer. We, therefore, explored our data by altering the cutoff for CINtec PLUS positivity to be >1 positive cell. This cutoff resulted in a 47% increase in false-negatives (ie, CIN-2/3 scored as CINtec PLUSnegative) and a 49% increase in true-negatives. This means that although a more stringent cutoff would lead to higher specificity, it would greatly compromise the sensitivity of CINtec PLUS. 
Future Perspectives
Undoubtedly, HPV testing is the most sensitive screening technique 26, 27 ; indeed, it permits HPV-negative women to be referred back to routine screening (ie, a screening interval of 3 or 5 years). 28 Women infected with high-risk HPV types other than HPV-16/18 and negative cytology have a lower risk for developing CIN-2/3 29 and, therefore, may benefit from combination testing to determine whether immediate colposcopy and biopsy are warranted. In April 2015, Norway introduced a pilot project for the implementation of HPV testing in primary screening; it involved a subset of women in the NCCSP. An important effect of HPV testing in primary screening is that the sensitivity of cytology is improved when only HPVpositive specimens are evaluated. 30 In a setting where HPV testing is used for primary screening, HPV-positive women with ASCUS cytology or worse are immediately referred for colposcopy. Hence, the use of p16/Ki-67 dual staining as an adjunct to cytology could simplify decision making and reduce the time to treatment 19 and could certainly translate into a reduction of the resources needed. Nonetheless, the expenses related to applying a test in a screening program should be thoroughly evaluated before the practice is implemented. The development of a cervical lesion is determined by interactions between an individual's immune response, viral factors, and cellular mechanisms.
Unfortunately, at present, we do not have biomarkers that take all these factors into consideration. 31 In conclusion, in a population of women who were HPV-positive at their secondary screening, requiring a positive result for both p16/Ki-67 dual staining and cytology increased the specificity for detecting both CIN-2/3 and CIN-3 in comparison with cytology or p16/Ki-67 dual staining alone while keeping the sensitivity at an acceptable level. As a result, p16/Ki-67 dual staining for HPVpositive women with normal, ASCUS, or LSIL cytology could serve as an adjunct to cytology for determining the necessity for referral for colposcopy.
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